NovoBiome and Inserm form new collaboration to simulate human intestinal physiology streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NovoBiome and INRAE, a new Associated Partner Laboratory on globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Novobiome: NovoBiome launched to revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis
the
targeting
microbiome NASH
after obesity and T
Paris
May 2021: NovoBiome ( the Company ), a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome, has been launched today by a team of world-leading experts in the fields of Microbiology and Artificial Intelligence. The new company will develop breakthrough Live Biotherapeutics Products (LBPs)
1 targeting the microbiome-gut-liver axis. NovoBiome is building a comprehensive, disruptive ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.
NovoBiome s first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). NAFLD has become the most common cause of